A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis

Borets O.G.; Govorukhina N.F.; Zverev K.V.; Boĭko A.N.

doi:https://doi.org/10.17116/jnevro20161162263-67

Borets O.G.

Moskovskiĭ gorodskoĭ tsentr rasseiannogo skleroza (gorodskaia klinicheskaia bol'nitsa #11 Departamenta zdravookhraneniia Moskvy);
kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universtiteta

Govorukhina N.F.

City Clinical Hospital №71, Moscow

Zverev K.V.

City Clinical Hospital №71, Moscow

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis

Authors:

Borets O.G., Govorukhina N.F., Zverev K.V., Boĭko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2‑2): 63‑67

DOI: 10.17116/jnevro20161162263-67

Read: 1325 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Borets OG, Govorukhina NF, Zverev KV, Boĭko AN. A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2‑2):63‑67. (In Russ.)
https://doi.org/10.17116/jnevro20161162263-67

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Stress and sleep: Neurobiological aspects and modern options of insomnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68

Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77

Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry. Russian Cardiology Bulletin. 2025;(1):22-38

Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coronary intervention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200

Influence of griseofulvin on intestinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):185-190

A clinical case of X-linked adrenoleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107

Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology. Russian Annals of Ophthalmology. 2025;(2):106-116

Postoperative peritonitis: epidemiology, diagnosis, surgical treatment and prognosis. Pirogov Russian Journal of Surgery. 2025;(6):104-111

Abstract:

Objective — to compare the results of treatment of multiple sclerosis (MS) with genfaxon, cinnovex and rebif. Material and methods. The drugs were used in the treatment of 80 patients of the Moscow West administrative okrug during 2014—2015. Thirty patients were treated with genfaxon, 20 with cinnoVex and 30 with the original drug rebif. Results and conclusion. Twenty-five percent of patients treated with cinnoVex were withdrawn from the study due to the non-efficacy (mean frequency of relapses was the same before and after treatment). A significant decrease of relapses was noted in patients treated with genfaxon. The high frequency of side-effects was the major problem in the treatment withgenfaxon. Due to this reason, some patients stopped treatment.A significant decrease of relapses was noted in patients treated with rebif though aversive effects were frequent during the first year of treatment. The effects of biosimilars found in this study are in line with earlier reports. Therefore, the increase of the quality of interferon-beta-1a biosimilars used for MS treatment is needed.

Keywords:

multiple sclerosis

treatment

β-interferon-1a

biosimilars

Authors:

Borets O.G.

Govorukhina N.F.

City Clinical Hospital №71, Moscow

Zverev K.V.

City Clinical Hospital №71, Moscow

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

Close metadata

References:

Boiko A.N., Kukel' T.M., Lysenko M.A., Vdovichenko T.V., Gusev E.I. Klinicheskaya epidemiologiya rasseyannogo skleroza v gorode Moskve: Opisatel'naya epidemiologiya na primere populyatsii odnogo iz okrugov goroda. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;10(2):8-14.
Kukel' T.M., Boiko A.N., Lysenko M.A., Vdovichenko T.V., Gusev E.I. Epidemiologicheskie kharakteristiki rasseyannogo skleroza v Moskve. Prakticheskaya meditsina (spetsvypusk). 2013;68:1-1:31-32.
Baidina E.V., Boiko A.N., Bryukhov V.V., Gusev E.I., Dubchak L.V., Zavalishin I.A., Ivanov R.A., Kotov S.V., Krotenkova M.V., Par V.I., Shmidt T.E., Shchur S.G., Yakhno N.N. Rezul'taty klinicheskogo issledovaniya rossiiskogo bioanaloga interferona β-1b. Nevrologicheskii vestnik. 2010;XLII:1:41-48.
Popova E.V., Boiko A.N., Vasil'ev A.V., Davydovskaya M.V., Zavalishin I.A., Kotov S.V., Krotenkova M.V., Khachanova N.V., Sharanova S.N., Shchur S.G., Yakushina T.I. Rezul'taty sravnitel'nogo klinicheskogo issledovaniya rossiiskogo bioanaloga interferona β-1b (infibeta). Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. 2012;112:5:56-61.
Popova E.V., Boiko A.N., Vasil'ev A.V., Davydovskaya M.V., Zavalishin I.A., Kotov S.V., Krotenkova M.V., Khachanova N.V., Sharanova S.N., Shchur S.G., Yakushina T.I. Rezul'taty klinicheskogo issledovaniya preparata infibeta (II-III faza). Rekomendatsii po perevodu patsientov s rasseyannym sklerozom na bioanalogi. Consilium Medicum. 2012;14 (2):2-7.
Popova E.V., Davydovskaya M.V., Demina T.L., Kol'yak E.V., Kukel' T.M., Lashch N.Yu., Popova N.F., Khachanova N.V., Shchur S.G., Boiko A.N. Pervyi opyt primeneniya rossiiskogo bioanaloga interferona β-1b (infibeta) v povsednevnoi praktike tsentra rasseyannogo skleroza. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;10(2):93-96.
Borets O.G., Davydovskaya M.V., Demina T.L., Lashch N.Yu., Popova N.F., Popova E.V., Khachanova N.V., Khasaeva M.V., Shchur S.G., Boiko A.N. Opyt primeneniya bioanalogov interferona β-1α (sinnoveks i genfakson-44) v Moskovskom gorodskom tsentre rasseyannogo skleroza. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;2 2):51-56.
Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
Tekhnologiya lecheniya rasseyannogo skleroza s ispol'zovaniem immunomoduliruyushchikh preparatov dlitel'nogo primeneniya PITRS — β-interferonov i glatiramera atsetata. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2011;111:2:2:86-92.
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler. 1995;1(2):118-135.
Boiko A.N., Batysheva T.T., Bykova O.V., Davydovskaya M.F., Demina T.L., Lashch N.Yu., Nankina I.A., Ovcharov V.V., Popova E.V., Popova N.F., Ryabukhina O.V., Khachanova N.V., Shchur S.G., Gusev E.I. Sravnenie effektivnosti i perenosimosti interferona β-1a dlya vnutrimyshechnogo ispol'zovaniya u vzroslykh i podrostkov s remittiruyushchim rasseyannym sklerozom. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;2(2):98-103.
Vlasov Ya.V., Popova E.V. Obosnovanie neobkhodimosti povysheniya kachestva primenyaemykh v Rossiiskoi Federatsii preparatov, izmenyayushchikh techenie rasseyannogo skleroza (PITRS) Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115:2:57-60.